Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways

Franck Morceau, Sébastien Chateauvieux, Marion Orsini, Anne Trécul, Mario Dicato, Marc Diederich*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

35 Citations (Scopus)

Abstract

In addition to apoptosis resistance and cell proliferation capacities, the undifferentiated state also characterizes most cancer cells, especially leukemia cells. Cell differentiation is a multifaceted process that depends on complex regulatory networks that involve transcriptional, post-transcriptional and epigenetic regulation of gene expression. The time- and spatially-dependent expression of lineage-specific genes and genes that control cell growth and cell death is implicated in the process of maturation. The induction of cancer cell differentiation is considered an alternative approach to elicit cell death and proliferation arrest. Differentiation therapy has mainly been developed to treat acute myeloid leukemia, notably with all-trans retinoic acid (ATRA). Numerous molecules from diverse natural or synthetic origins are effective alone or in association with ATRA in both in vitro and in vivo experiments. During the last two decades, pharmaceuticals and natural compounds with various chemical structures, including alkaloids, flavonoids and polyphenols, were identified as potential differentiating agents of hematopoietic pathways and osteogenesis.

Original languageEnglish
Pages (from-to)785-797
Number of pages13
JournalBiotechnology Advances
Volume33
Issue number6
DOIs
Publication statusPublished - 1 Nov 2015
Externally publishedYes

Keywords

  • Cancer
  • Differentiation therapy
  • Drug development
  • Gene expression
  • Leukemia
  • Natural compounds

Fingerprint

Dive into the research topics of 'Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways'. Together they form a unique fingerprint.

Cite this